Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , July 17, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 15, 2020 , the Compensation Committee of its Board of Directors granted to six new employees inducement stock options to purchase an aggregate of 35,850 shares of its common stock and
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , June 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 80,250 shares of its common stock to 12 new employees and
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
SAN DIEGO , June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global clinical
View HTML
Toggle Summary Arena Pharmaceuticals Announces R&D Leadership Transition
- Dr. Preston Klassen, Executive Vice President, Head of Research and Development, resigning   - Dr. Chris Cabell appointed Executive Vice President, Head of Research and Development, and Chief Medical Officer SAN DIEGO , June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , June 1, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant
View HTML
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , May 28, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , May 27, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena.
View HTML
Toggle Summary Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, meeting the high end of targeted enrollment range, topline data expected Q4 2020 - Etrasimod ELEVATE UC Program remains on track - Updated guidance for newly initiated trials, and certain trials in planning
View HTML
Toggle Summary Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SAN DIEGO , May 22, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being
View HTML